Author Question: Use of an externally powered, small-volume nebulizer for aerosol delivery during partial ... (Read 84 times)

V@ndy87

  • Hero Member
  • *****
  • Posts: 571
Use of an externally powered, small-volume nebulizer for aerosol delivery during partial ventila-tory support with PSV may cause which of the following?
 
  1. High VT alarm activation
  2. Triggering difficulties
  3. Low pressure alarm activation
  4. Ventilator inoperative alarm
  a. 1 and 2
  b. 2 and 3
  c. 3 and 4
  d. 1 and 4

Question 2

The graphics below indicate which of the following conditions?
 
  a. Auto-PEEP
  b. Active exhalation
  c. Inadequate flow setting
  d. Increased expiratory resistance



Kaytorgator

  • Sr. Member
  • ****
  • Posts: 345
Answer to Question 1

ANS: A
When a continuous flow nebulizer is placed between the patient and the sensing mechanism, the patient often finds it more difficult to generate the effort to trigger the ventilator. High VT deliv-ery can occur when externally powered, small-volume nebulizers are used for aerosol delivery.

Answer to Question 2

ANS: C
Inadequate flow during mechanical ventilation is shown in the figure on the pressure-time graph-ic by the concave pressure tracing while the flow curve is constant. Auto PEEP would be evident on the flow graphic when the exhaled flow does not return to zero before the beginning of the next breath. Active exhalation would be evident on the pressure graphic as a peak at the end of inspiration. Increased airway resistance would show as the exhaled flow not returning all the way to zero by the time the next breath begins.



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
 

Did you know?

Signs and symptoms of a drug overdose include losing consciousness, fever or sweating, breathing problems, abnormal pulse, and changes in skin color.

Did you know?

Multiple experimental evidences have confirmed that at the molecular level, cancer is caused by lesions in cellular DNA.

Did you know?

Vaccines prevent between 2.5 and 4 million deaths every year.

Did you know?

Fatal fungal infections may be able to resist newer antifungal drugs. Globally, fungal infections are often fatal due to the lack of access to multiple antifungals, which may be required to be utilized in combination. Single antifungals may not be enough to stop a fungal infection from causing the death of a patient.

Did you know?

Before a vaccine is licensed in the USA, the Food and Drug Administration (FDA) reviews it for safety and effectiveness. The CDC then reviews all studies again, as well as the American Academy of Pediatrics and the American Academy of Family Physicians. Every lot of vaccine is tested before administration to the public, and the FDA regularly inspects vaccine manufacturers' facilities.

For a complete list of videos, visit our video library